Schering's strategy

Published: 9-Feb-2002


German giant Schering has taken a further step towards its goal of becoming a major player in the global radiopharmaceutical market with the purchase of the outstanding 40% of French company CIS bio international from Areva.

'The acquisition supports Schering's strategy to become a substantial player in the global radiopharmaceutical market,' said Hans-Michael Rook, head of diagnostics and radiopharmaceuticals. 'The area of oncological radiopharmaceuticals presents a particularly attractive opportunity given Schering's existing expertise in oncology and the potential for synergies between its diagnostics and therapeutics businesses.'

You may also like